“OUR SUMMER NEWSLETTER IS HERE!”
Summer 2015
Dr. John Hoskins Discusses Age-Related Macular Degeneration
Dr. John Hoskins discusses on Educational TV Age-Related Macular Degeneration (AMD) and what Southeastern Retina Associates is doing to treat this number 1 reason for blindness for those over 50. AMD is a type of macular degeneration that happens as the result of aging. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead.
Recognized Nationally for Clinical Excellence
KNOXVILLE, TN (January 30, 2015): Southeastern Retina Associates recently received a prestigious industry award for its contributions to advancing medical research of diabetes-induced retinal disorders. Southeastern Retina Associates was awarded the Top Site Award for 2014 and 2013 by the Diabetic Retinopathy Clinical Research (DRCR) Network for demonstrating outstanding performance in the DRCR Network. “We are honored to be acknowledged again at this level for our clinical excellence,” said Dr. Joseph M. Googe, Jr. of Southeastern Retina Associates. “Our entire staff has always been committed to providing the finest care possible and offering our patients the newest and best treatments of vision-threatening diseases.” The DRCR is a collaborative network funded by the National Eye Institute (NIH) and is dedicated to clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. The DRCR includes over 120 participating sites (offices) with over 320 physicians throughout the United States. “If you are diabetic and have vision issues, as a patient of Southeastern Retina Associates, you can be assured you have the most experienced medical team in the region working to preserve your eyesight,” said Googe. “We have been leading clinical trials for more than 15 years and continue to advance leading edge […]
Diabetes is the leading cause of preventable blindness.
See recent local TV news segments on how diabetes is the leading cause of preventable blindness. Clinical trial aims to help diabetics save their vision Controlling Diabetes To Prevent Blindness Eye problems for diabetics
Introducing Dr. Rohan Shah, M.D.
Join us in welcoming Dr. Shah to our Chattanooga office! Dr. Rohan Shah is a Tennessee native and grew up in Lawrenceburg, TN. He is a graduate of the Vanderbilt University School of Medicine and is board certified by the American Board of Ophthalmology. About Dr. Rohan Shah, M.D.
New Office Location in Rome, GA is now OPEN!
Our new Rome, GA office is now open at 210 Redmond Rd, Rome, Georgia. Please come visit us.
New Office Location in Harriman is now OPEN!
Our new Harriman office is now open at 1855 Tanner Way Suite 120, Kingston, Tennessee. Please come visit us.
New Harriman Office Location Coming Soon!
Our new Harriman office is opening June 23 at 1855 Tanner Way Suite 10, Kingston, Tennessee. Please come visit us.
Understanding and Preventing Age Related Macular Degeneration
Dr. Richard I. Breazeale is featured on WTVC-TV in Chattanooga, TN to discuss age related macular degeneration (AMD), the leading cause of vision loss and blindess in patients over 50.
Southeastern Retina Associates Partners With NIH in Clinical Trial
Southeastern Retina Associates is one of 100 sites across the country partnering with the National Institutes of Health (NIH) in a study of the use of the drug Eylea as an injectable eye treatment for diabetic patients with vision problems. The study will evaluate the effectiveness of the new treatment compared to laser therapy, the current gold standard treatment for a complication of diabetic retinopathy in which patients suffer bleeding in the retina. The condition can result in blindness if not treated successfully. Patients taking part in the study will get either injections of Eylea, laser therapy, or simply be observed for changes. Steve Perkins, M.D., of Southeastern Retina Associates is recruiting diabetics whose vision remains relatively undamaged to participate in the study. Injections of Eylea are free, though patients or their insurance may be required to pay other costs involving regular eye care. Patients interested in participating in the study may call 865-588-0811 for more information.